| Project/Area Number |
16390159
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
HIGUCHI Shun Kyushu University, Faculty of Pharmaceutical Sciences, Prof., 大学院・薬学研究院, 教授 (40218699)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHDO Shigehiro Kyushu University, Faculty of Pharmaceutical Sciences, Prof., 大学院・薬学研究院, 教授 (00223884)
TO Hideto Kyushu University, Faculty of Pharmaceutical Sciences, Research Associate, 大学院・薬学研究院, 助手 (90346809)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥15,200,000 (Direct Cost: ¥15,200,000)
Fiscal Year 2005: ¥4,400,000 (Direct Cost: ¥4,400,000)
Fiscal Year 2004: ¥10,800,000 (Direct Cost: ¥10,800,000)
|
|---|
| Keywords | dosing schedule / chemotherapy / docetaxel / adriamycin / cisplatin / adverse effect / antitumor effect / decetaxel |
|---|
| Research Abstract |
The purpose of this study was to establish the most suitable dosing-schedule (dosing-interval, dosing-sequence and dosing-time) to relieve severe adverse effects for a few combination of antitumor drugs.
1.combination of adriamycin (ADR) and docetaxel (DOC)
The DOC-ADR group in which ADR is administered at 12 h after DOC injection significantly reduces the leucopenia and body weight gain compared with all groups.
The therapeutic index of the combined chemotherapy can be improved by administering ADR and DOC at the time when the most adverse effects are relieved in each drug.
2.combination of cisplatin (CDDP) and docetaxel (DOC)
The intermittent dosing groups (ADR-DOC and DOC-ADR) were administered the second drug at 12 h after the first drug administration significantly reduces the side effects compared with the simultaneous dosing group (ADR/DOC) were both adriamycin (ADR) and docetaxel (DOC) were simultaneously administered.
3.combination of irinotecan hydrochloride (CPT-11) and docetaxel (DOC)
The combined chemotherapy was improved by administering CPT-11 and DOC at the time when the most adverse effects are relieved in each drug.
|
